About the Authors
- Ulrich Deuschle, Andreas Schulz, Thomas Schlüter, Olaf Kinzel, Claus Kremoser
- Department of Research, Phenex Pharmaceuticals AG, Heidelberg, Germany
- Julia Schüler
- Department of In Vivo Tumor Biology, Oncotest GmbH, Freiburg, Germany
- Ulrich Abel
- Department of Medicinal Chemistry, Merz Pharmaceuticals GmbH, Frankfurt, Germany
UA is a full-time employee of Merz Pharmaceuticals GmbH, JS is a full-time employee of Oncotest GmbH and the rest of the authors are full-time employees of Phenex Pharmaceuticals AG. UD and CK are co-founders of Phenex Pharmaceuticals AG and UD, AS and CK do own shares of Phenex Pharmaceuticals AG. Kremoser C, Abel U, Steeneck C, Kinzel O (2011) Patent Application WO2011/020615 Novel FXR (NR1H4) binding and activity modulating compounds. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.
Conceived and designed the experiments: UD JS AS TS. Performed the experiments: UD AS TS. Analyzed the data: UD JS AS TS. Contributed reagents/materials/analysis tools: UD AS UA OK. Wrote the paper: UD CK.